Product Description
Betamethasone topical is used to treat the itching, redness, dryness, crusting, scaling, inflammation, and discomfort of various skin conditions, including psoriasis (a skin disease in which red, scaly patches form on some areas of the body) and eczema (a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes). Betamethasone is in a class of medications called corticosteroids. It works by activating natural substances in the skin to reduce swelling, redness, and itching.
Mechanisms of Action: GR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical, Intramuscular
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: LEO Pharma
Company Location: Europe
Company Founding Year: 1908
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, China, Denmark, France, Germany, Italy, Mexico, Netherlands, New Zealand, Poland, Spain, Turkey, Unknown Location
Active Clinical Trial Count: 16
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Bursitis|Candidiasis|Pain Unspecified|Psoriasis|Retinitis Pigmentosa|Rhinitis, Allergic|Synovitis|Tendinopathy
Phase 2: Anesthesia Related|Chronic Rhinosinusitis|Fallopian Tube Cancer|Ovarian Cancer|Pain, Postoperative|Peritoneal Cancer|Shoulder Pain|Vision, Low
Phase 1: Dermatitis, Atopic|Healthy Volunteers|Oncology Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12624000621516 |
ACTRN12624000621516 | P1 |
Completed |
Psoriasis|Dermatitis, Atopic |
2024-06-06 |
2026-02-15 |
Primary Completion Date|Start Date|Treatments|Trial Status |
|
ACTRN12618000798268p |
2006-7041-83/hah | P1 |
Not yet recruiting |
Oncology Unspecified|Healthy Volunteers |
2018-10-22 |
|||
NCT07357831 |
HDM3015-301 | P3 |
Recruiting |
Psoriasis |
2026-10-10 |
12% |
2026-01-28 |
Primary Endpoints|Start Date|Treatments|Trial Status |
2022-501415-14-00 |
21-01/ClotriBet-S | P3 |
Recruiting |
Candidiasis |
2025-12-01 |
2025-05-02 |
Treatments |
|
NCT07328022 |
SIL-30953-III-24(1) | P3 |
Completed |
Bursitis|Synovitis|Tendinopathy |
2025-08-20 |
5% |
2026-01-09 |
|
NCT06916884 |
DESCUBRA | P3 |
Recruiting |
Rhinitis, Allergic |
2025-05-11 |
41% |
2025-04-09 |
|
2016-000407-84 |
2016-000407-84 | P3 |
Active, not recruiting |
Pain Unspecified |
2018-04-13 |
2022-03-13 |
Treatments |
|
2022-502983-19-00 |
ZNâc3-005 | P2 |
Recruiting |
Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cancer |
2027-09-01 |
2025-05-02 |
Treatments |
|
NCT07131657 |
PF_002 | P2 |
Completed |
Shoulder Pain|Vision, Low|Anesthesia Related|Pain, Postoperative |
2025-12-03 |
12% |
2026-01-13 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date |
NCT05882903 |
FESS | P2 |
Recruiting |
Chronic Rhinosinusitis |
2025-06-01 |
12% |
2024-11-13 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
2024-511411-25-00 |
MGT-RPGR-022 | P3 |
Active, not recruiting |
Retinitis Pigmentosa |
2029-12-19 |
2025-05-02 |
Treatments |
|
NCT06781632 |
RopiCloBet | P1 |
Completed |
Healthy Volunteers |
2025-02-20 |
88% |
2025-05-20 |
|
ACTRN12624000107527 |
ACTRN12624000107527 | P1 |
Completed |
Dermatitis, Atopic|Psoriasis |
2024-04-17 |
2026-02-15 |
||
CTR20222869 |
CTR20222869 | P2 |
Completed |
Unknown |
2023-06-18 |
2025-06-01 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT06863701 |
SIL-30953-III-23(1) | P3 |
Recruiting |
Unknown |
2026-12-31 |
39% |
2025-03-08 |
|
CTR20233982 |
CTR20233982 | P3 |
Active, not recruiting |
Unknown |
None |
2025-11-02 |
Patient Enrollment|Treatments|Trial Status |